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Clinical Case
Light chain amyloidosis 
poses a unique diagnostic 
challenge due to its wide 
array of nonspecific 
clinical manifestations. 
However, making a 
prompt diagnosis may 
substantially improve 
clinical outcomes.  
Multiple diagnostic pitfalls exist, including markedly 
low incidence of the disease and variable multi-organ 
involvement with varying degrees of severity.  Light chain 
amyloidosis typically is a disease of older adults and 
incidence increases with advancing age. The median age of 
diagnosis is the seventh decade of life.  This disease does 
have a male predominance, but geographic location and 
race have not been identified as significant variables.1  Long 
term studies have demonstrated a correlation in patients 
with monoclonal gammopathy of undetermined significance 
(MGUS) in that they may progress to multiple myeloma, IgM 
lymphoma, primary amyloidosis, macroglobulinemia, CLL, 
or plasmacytoma at a rate of 1% per year.2  Diagnosis is 
achieved with identification of amyloid fibrils using Congo 
red staining which results in an apple green birefringence 
appearance on histologic review.  The goal is to collect a 
biopsy from an affected organ with consideration of safety, 
procedure complexity, and typical expected yield.   
The focus of treatment for light chain amyloidosis is control of the 
underlying plasma cell disorder with chemotherapy to suppress 
synthesis of immunoglobulin light chains.  Promising results have 
been seen with high-dose chemotherapy in combination with stem cell 
transplantation, however, as with this patient, safe administration may 
not be feasible or recommended in patients with widespread disease at 
diagnosis.10  The process of diagnosis itself may be a challenge if biopsy 
tissue samples are not well-chosen in regards to expected tissue yield.  
The inability to capture positive staining using this patient’s synovial 
fluid was most likely due to the fact that synovial fluid is less than the 
minimum recommended 6 micron thickness for adequate staining of 
amyloid fibrils.11,12  Although the gold standard for diagnosis is biopsy 
tissue staining in order to demonstrate amyloid fibrils, supplemental 
studies such as cardiac MRI may be accurate noninvasive methods 
of providing support for identification of additional organ system 
involvement.8 
This patient’s multi-system involvement had previously been unexplained 
and treated as individual entities.  The timeframe of her macroglossia 
alone was suspected to have to progressed over at least three years.  
Her final diagnosis was unfortunately made when her disease was 
significantly advanced, thus limiting her treatment options.   This case 
highlights the need to look for the possibility of a unifying diagnosis early 
in the disease timeline for patients with a constellation of symptoms to 
provide the best chance for increased overall survival.13
Conclusion
Biopsy site locations and associated diagnostic success rate.3-5
The patient is a 70 year old female with notable history of mediastinal adenopathy, COPD, dCHF, MGUS (lamda light chain), and suspected 
chronic tongue angioedema leading to tracheostomy.  She presented with acute hypoxic respiratory failure.  Findings on admission 
included fever, periorbital pupura, low-voltage EKG, proteinuria, pulmonary nodules, and polyarthralgia.  She was treated with empiric 
antibiotics for suspected pneumonia, steroids, and an anti-histamine due to concern for angioedema.  Her angioedema was not found 
to be IgE-related or consistent with hereditary angioedema.  Direct examination via flexible laryngoscopy did not show laryngeal or 
tongue base edema.  Fat pad biopsy was found to be consistent with amyloidosis.  Rather than pursuing cardiac biopsy to demonstrate 
definitive cardiac involvement of amyloidosis, cardiac MRI was obtained.  This study showed diffuse subendocardial delayed gadolinium 
enhancement in the thickened left myocardium with a markedly hypodense blood pool, a finding that has been described with amyloidosis.  
Positive identification of amyloidosis with cardiac involvement portends a poor prognosis.  The patient also developed progressive 
polyarthralgia with significant left knee effusion during her hospitalization.  This was initially suspected to be crystalline in etiology.  
Synovial fluid profile status post joint aspiration revealed the absence of crystals and WBC 5860/cmm consistent with inflammatory 
process. Given her constellation of clinical findings this was suspected to also be related to her amyloidosis.  Congo red staining was 
attempted, however synovial fluid was not successfully stained.  She was offered palliative options without bone marrow transplantation 
for her systemic disease such as melphalan/dexamethasone or a bortezomid-based regimen (such as CyBorD).  Unfortunately there were 
concerns regarding her ability to tolerate these treatments and she ultimately chose not to proceed with these therapies. 
Diagnostic criteria for light chain amyloidosis developed by the Mayo Clinic and the 
International Myeloma Working Group.  ALL criteria should be present, however this 
diagnosis may still be established in 2-3% of patients with light chain amyloidosis.9
Patient with periorbital purpura and massive macroglossia.
Apple-green birefringence on fat pad biopsy slide status post 
Congo red staining under polarized light. 
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  Tissue Sample Typical Yield
Abdominal fat pad 60-80%
Rectal biopsy 50-70%
Kidney/liver biopsy Greater than 90%
Bone marrow biopsy 50-55%
Skin 50%
 
 Amyloidosis Manifestations6-8 Specific Manifestations Present
Renal disease Hematuria, proteinuria
Cardiomyopathy Chronic dCHF, low voltage EKG with poor R wave progression, cardiomegaly, left ventricular thickening
Gastrointestinal disease Ileus, constipation, hypoalbuminemia , elevated alkaline phosphatase
Neurologic abnormalities None identified
Musculoskeletal disease Macroglossia, “shoulder pad” sign, polyarthropathy with effusions 
Hematologic/lymphatic abnormalities MGUS, elevated PT, mediastinal adenopathy
Pulmonary disease Parenchymal nodules, persistent small bilateral pleural effusions
Skin manifestations Periorbital purpura
 
 Diagnostic Criteria Presence
Presence of an amyloid-related 
systemic syndrome felt to be due to 
amyloid and NOT another common 
disease (i.e. DM, HTN)
Yes
Positive amyloid staining by Congo red 
in any tissue or presence of amyloid 
fibrils on electron microscopy
Yes: abdominal fat pad biopsy
Evidence that the amyloid is light 
chain-related established by direct 
examination of amyloid
Not performed
Evidence of a monoclonal plasma cell 
proliferative disorder Yes: MGUS
Introduction
